Fabio Bozzi

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. ncbi request reprint Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma
    Fabio Bozzi
    Department of Anatomic Pathology, Experimental Molecular Pathology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Anticancer Res 28:1565-9. 2008
  2. ncbi request reprint Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma
    Fabio Bozzi
    Department of Medical Oncology, Division of Pediatrics, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Diagn Mol Pathol 13:135-43. 2004
  3. ncbi request reprint Detecting CD56+/NB84+/CD45- immunophenotype in the bone marrow of patients with metastatic neuroblastoma using flow cytometry
    Fabio Bozzi
    Department of Medical Oncology, Division of Pediatrics, C Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Anticancer Res 26:3281-7. 2006
  4. doi request reprint High CD133 expression levels in gastrointestinal stromal tumors
    Fabio Bozzi
    Laboratory of Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    Cytometry B Clin Cytom 80:238-47. 2011
  5. pmc Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy
    Luca Da Riva
    Proteomics Laboratory, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    J Transl Med 9:158. 2011
  6. doi request reprint In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas
    Fabio Bozzi
    Laboratory of Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
    Lab Invest 93:1232-40. 2013
  7. doi request reprint Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma
    Tiziana Negri
    Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Genes Chromosomes Cancer 51:111-26. 2012
  8. doi request reprint Functional mapping of receptor tyrosine kinases in myxoid liposarcoma
    Tiziana Negri
    Laboratory of Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Clin Cancer Res 16:3581-93. 2010
  9. ncbi request reprint Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors
    Fabio Bozzi
    Experimental Molecular Pathology Unit, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy
    Cancer 109:1638-45. 2007
  10. doi request reprint Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients
    Lorena Passoni
    Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
    Cancer Res 69:7338-46. 2009

Detail Information

Publications15

  1. ncbi request reprint Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma
    Fabio Bozzi
    Department of Anatomic Pathology, Experimental Molecular Pathology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Anticancer Res 28:1565-9. 2008
    ..Myogenin (Myf4), a specific molecular RMS marker, was also investigated in the same samples. Since neuroblastoma (NB) metastasizes to the BM, the potential application of cytometry in differential diagnosis was explored...
  2. ncbi request reprint Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma
    Fabio Bozzi
    Department of Medical Oncology, Division of Pediatrics, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Diagn Mol Pathol 13:135-43. 2004
    ..These results suggest that finding DDC mRNA in NB patients could be a potential marker for minimal residual disease study...
  3. ncbi request reprint Detecting CD56+/NB84+/CD45- immunophenotype in the bone marrow of patients with metastatic neuroblastoma using flow cytometry
    Fabio Bozzi
    Department of Medical Oncology, Division of Pediatrics, C Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Anticancer Res 26:3281-7. 2006
    ..In order to identify neuroblastoma cells infiltrating the bone marrow, a triple-color flow-cytometric assay was developed combining CD56 and CD45 with the intracellular anti-NB84 specific antibody...
  4. doi request reprint High CD133 expression levels in gastrointestinal stromal tumors
    Fabio Bozzi
    Laboratory of Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    Cytometry B Clin Cytom 80:238-47. 2011
    ..It is therefore possible that the acquisition of secondary KIT mutations during imatinib treatment may occur in putative GIST CSCs...
  5. pmc Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy
    Luca Da Riva
    Proteomics Laboratory, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    J Transl Med 9:158. 2011
    ..Recently, apoptosis and autophagy were suggested as possible alternative mechanisms of pharmacological response...
  6. doi request reprint In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas
    Fabio Bozzi
    Laboratory of Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
    Lab Invest 93:1232-40. 2013
    ..However, our findings predict heterogeneous responses depending on the relative expression of mdm2, mdm2-b, mdmx, and mdmx-s transcripts and proteins. ..
  7. doi request reprint Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma
    Tiziana Negri
    Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Genes Chromosomes Cancer 51:111-26. 2012
    ..2011 Wiley Periodicals, Inc...
  8. doi request reprint Functional mapping of receptor tyrosine kinases in myxoid liposarcoma
    Tiziana Negri
    Laboratory of Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Clin Cancer Res 16:3581-93. 2010
    ....
  9. ncbi request reprint Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors
    Fabio Bozzi
    Experimental Molecular Pathology Unit, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy
    Cancer 109:1638-45. 2007
    ..The aim of the study was to investigate the expression/activation of KIT, PDGFRalpha, and PDGFRbeta receptor tyrosine kinases (RTKs) as potential therapeutic targets in ESFT...
  10. doi request reprint Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients
    Lorena Passoni
    Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
    Cancer Res 69:7338-46. 2009
    ..Alternative mechanisms other than direct mutations and/or gene amplification regulate the ALK level of expression in NBL cells. Wild-type ALK is a potential therapeutic target for advanced/metastatic NBLs...
  11. pmc Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation
    Fabio Bozzi
    Experimental Molecular Pathology, Department of Pathology, Istituto Nazionale Tumori, Milan, Italy
    Transl Oncol 1:95-101. 2008
    ..Although they need to be confirmed in larger series, these preliminary data suggest that therapeutic strategies including specific inhibitors of the phosphatidylinositol 3-kinase/Akt pathway might be exploited in SS...
  12. pmc Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma
    Maura Massimino
    Pediatric Oncology Unit, Istituto Nazionale Tumori, Milan, Italy
    Neuro Oncol 7:41-8. 2005
    ..Sequential and high-dose chemotherapy can be afforded in front-line therapy of childhood malignant glioma without excessive morbidity and rather encouraging results...
  13. ncbi request reprint Establishment and characterization of a new Ewing's sarcoma cell line from a malignant pleural effusion
    Roberta Schiavo
    Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
    Anticancer Res 27:3273-8. 2007
    ..In the present study, we report the establishment and characterization of a primary Ewing's sarcoma cell line (LDS-Falck 01)...
  14. ncbi request reprint Peripheral blood stem cell collection in pediatric patients: feasibility of leukapheresis under anesthesia in uncompliant small children with solid tumors
    Fernando Ravagnani
    Immunohematology and Transfusion Medicine Service, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Clin Apher 21:85-91. 2006
    ..8 x 10(6)/kg/leukapheresis (range 1-117) and the median collection efficiency was 63.4% (range 25-100.6). Leukapheresis under anesthesia is feasible and safe in very low-weight children whose compliance is lacking due to age and disease...
  15. ncbi request reprint Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma
    Roberto Luksch
    Department of Medical Oncology, Pediatric Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 89:263-8. 2003
    ..An additional aim was to assess whether any correlation between the immune modifications and the clinical outcome could be found...